Conclusion
Although not a comprehensive listing, the areas discussed in this article are four of the most important issues that will
help to streamline the negotiations between a service provider and a project sponsor interested in partnering on the development
of a cell-culture medium. As the technology platforms continue to push new boundaries, we will need to continue to look for
new ways to realize and share the value of those discoveries. The collective lesson for our industry has been that technical
innovations in products and services must be matched with business innovation to continue to best serve patients.
It is clear that striking a balanced approach to the outsourcing discussion is crucial for achieving the project goals. An
imbalance in any of the four areas discussed will set the outsourcing relationship on the course to disappointment; however,
if done properly, a progressive philosophy on sharing risks and benefits will turn an arm's-length outsourcing relationship
into a productive collaboration.
Acknowledgments
The authors wish to thank Cindy Goldstein and Laurie Donahue-Hjelle for their editorial contributions to this article.
TRENT CARRIER is General Manager of PD-Direct Services, STEVE GORFIEN is an R&D Director—Cell Culture Products and Services, and BRIAN GRIFFITH is Division Contracts Counsel, all at Life Technologies, Trent.Carrier@lifetech.com
.
References
1. H. Eagle, Science, 122 (3168), 501–504 (1955).
2. Therapeutic Monoclonal Antibodies: World Market 2010–2015,
http://ReportLinker.com/ 2010.
3. W.C. Paul et al., BioProcess Int. 7 (8), (2009).
4. D. Zhao et al., Biopharm Int. 21 (6) (2008).
5. T. Carrier et al., "High Throughput Technologies in Bioprocess Development," in Encyc. of Indust. Biotech., M. Flickinger, Ed. (Wiley, Hoboken, NJ, 2009).
6. S. Morris, BioProcess Int. 21 (12), 22-26, (2008).
|
